Skip to main content
Erschienen in: Drugs & Aging 2/2007

01.02.2007 | Review Article

Inappropriate Prevention of NSAID-Induced Gastrointestinal Events Among Long-Term Users in the Elderly

verfasst von: Dr Angel Lanas, Angel Ferrandez

Erschienen in: Drugs & Aging | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Although use of NSAIDs and aspirin (acetylsalicylic acid) is well known to be associated with gastrointestinal (GI) complications and potential mortality, these medications continue to be widely prescribed in the elderly. Age is a significant risk factor for NSAID-induced GI events; indeed, patients >75 years of age carry the highest risk and are similar in this respect to patients with a history of peptic ulcer. Prevention of NSAID-induced gastropathy is indicated in patients at risk. It is accepted that patients >60 years of age taking NSAIDs should participate in prevention strategies such as co-therapy with proton pump inhibitors (PPIs) or misoprostol, or use of cyclo-oxygenase (COX)-2 selective NSAIDs (also called coxibs). Although up to 33% of subjects with no risk factors who receive NSAIDs over-utilise GI preventive therapies, under-utilisation of gastroprotective therapy is more prevalent among those with risk factors, of which the most frequent is age. At least half of those at risk do not receive appropriate preventive therapy, either because they do not receive co-therapy with PPIs or misoprostol or are not treated with COX-2 selective NSAIDs, or because they receive co-therapy with antacids or histamine H2 receptor antagonists, which are not effective. Adherence to the prescribed preventive therapy is an additional problem for those who are prescribed a PPI or misoprostol. Over 30% of patients are non-adherent and the lowest rate of non-adherence is associated with the first NSAID prescription, which increases the risk of ulcer bleeding compared with those who are fully adherent. Predictors of nonadherence include long-term use of NSAIDs and a high average daily dose of NSAIDs. Predictors of adherence include a history of upper gastrointestinal events, anticoagulant use, rheumatological disease and use of low-dose salicylates, among others. Another important aspect is self-medication; this is common in the elderly, who also have several risk factors for GI complications, and may be a factor in over one-third of all NSAID-related complications. In summary, aging is a key risk factor for GI complications in patients taking NSAIDs. Appropriate prevention strategies should be used in the elderly and those at risk; special attention should be paid to compliance and self-medication.
Literatur
1.
Zurück zum Zitat Dubois RW, Melmed GY, Henning JM, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004; 19: 197–208PubMedCrossRef Dubois RW, Melmed GY, Henning JM, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004; 19: 197–208PubMedCrossRef
2.
Zurück zum Zitat Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004; 19Suppl. 1: 60–5PubMedCrossRef Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004; 19Suppl. 1: 60–5PubMedCrossRef
3.
Zurück zum Zitat Sturkenboom MCJM, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42Suppl. 3: 23–31 Sturkenboom MCJM, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42Suppl. 3: 23–31
4.
Zurück zum Zitat Laine L. Approaches to NSAID use in the high risk patient. Gastroenterology 2001; 120: 594–606PubMedCrossRef Laine L. Approaches to NSAID use in the high risk patient. Gastroenterology 2001; 120: 594–606PubMedCrossRef
5.
Zurück zum Zitat Brun J, Jones R. Non-steroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001; 110: 12S–3SPubMedCrossRef Brun J, Jones R. Non-steroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001; 110: 12S–3SPubMedCrossRef
6.
Zurück zum Zitat Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527–32PubMedCrossRef Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527–32PubMedCrossRef
7.
Zurück zum Zitat Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRef Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRef
8.
Zurück zum Zitat Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327(11): 749–54PubMedCrossRef Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327(11): 749–54PubMedCrossRef
9.
Zurück zum Zitat Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997; 112: 683–9PubMedCrossRef Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997; 112: 683–9PubMedCrossRef
10.
Zurück zum Zitat Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef
11.
Zurück zum Zitat Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100(8): 1685–93PubMedCrossRef Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100(8): 1685–93PubMedCrossRef
12.
Zurück zum Zitat Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123(4): 241–9PubMed Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123(4): 241–9PubMed
13.
Zurück zum Zitat Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123(4): 1006–12PubMedCrossRef Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123(4): 1006–12PubMedCrossRef
14.
Zurück zum Zitat Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006; 38(6): 415–28PubMedCrossRef Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006; 38(6): 415–28PubMedCrossRef
15.
Zurück zum Zitat Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects. Med Clin (Barc) 2000; 114Suppl. 3: 46–53 Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects. Med Clin (Barc) 2000; 114Suppl. 3: 46–53
16.
Zurück zum Zitat Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002; 287: 337–44PubMedCrossRef Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002; 287: 337–44PubMedCrossRef
17.
Zurück zum Zitat Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. J Gerontol Med Sci 1998; 53A: M59–63CrossRef Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. J Gerontol Med Sci 1998; 53A: M59–63CrossRef
18.
Zurück zum Zitat Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107–16PubMedCrossRef Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107–16PubMedCrossRef
19.
Zurück zum Zitat Pilotto A, Franceschi M, Vitale D, et al. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol 2006; 62: 65–73PubMedCrossRef Pilotto A, Franceschi M, Vitale D, et al. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol 2006; 62: 65–73PubMedCrossRef
20.
Zurück zum Zitat Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, lowdose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–9PubMedCrossRef Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, lowdose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–9PubMedCrossRef
21.
Zurück zum Zitat Lanas A, Garcia-Rodriguez L-A, Arroyo M-T, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006 Dec; 55(12): 1731–8PubMedCrossRef Lanas A, Garcia-Rodriguez L-A, Arroyo M-T, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006 Dec; 55(12): 1731–8PubMedCrossRef
22.
Zurück zum Zitat Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284(10): 1247–55PubMedCrossRef Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284(10): 1247–55PubMedCrossRef
23.
Zurück zum Zitat Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006; 119(3): 255–66PubMedCrossRef Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006; 119(3): 255–66PubMedCrossRef
24.
Zurück zum Zitat Rostom A, Wells G, Tugwell P, et al. Prevention of chronic NSAID induced upper gastrointestinal toxicity. Cochrane Database Syst Rev 2000; (3): CD002296 Rostom A, Wells G, Tugwell P, et al. Prevention of chronic NSAID induced upper gastrointestinal toxicity. Cochrane Database Syst Rev 2000; (3): CD002296
25.
Zurück zum Zitat Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334(22): 1435–9PubMedCrossRef Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334(22): 1435–9PubMedCrossRef
26.
Zurück zum Zitat ten Wolde S, Dijkmans BA, Janssen M, et al. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther 1996; 10(3): 347–51PubMedCrossRef ten Wolde S, Dijkmans BA, Janssen M, et al. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther 1996; 10(3): 347–51PubMedCrossRef
27.
Zurück zum Zitat Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112(6): 1817–22PubMedCrossRef Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112(6): 1817–22PubMedCrossRef
28.
Zurück zum Zitat Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Eng J Med 2002; 347(26): 2104–10CrossRef Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Eng J Med 2002; 347(26): 2104–10CrossRef
29.
Zurück zum Zitat Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118(11): 1271–8PubMedCrossRef Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118(11): 1271–8PubMedCrossRef
30.
Zurück zum Zitat Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127(4): 1038–43PubMedCrossRef Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127(4): 1038–43PubMedCrossRef
31.
Zurück zum Zitat Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329(7472): 948PubMedCrossRef Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329(7472): 948PubMedCrossRef
32.
Zurück zum Zitat Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100(5): 1028–36PubMedCrossRef Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100(5): 1028–36PubMedCrossRef
33.
Zurück zum Zitat Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162(2): 169–75PubMedCrossRef Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162(2): 169–75PubMedCrossRef
34.
Zurück zum Zitat Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 2003; 125(2): 389–95PubMedCrossRef Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 2003; 125(2): 389–95PubMedCrossRef
35.
Zurück zum Zitat Chan FKL, Wong VW, Suen BY, et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: a double blind, randomized trial [abstract no. A732]. Gastroenterology 2006; 130 (4 Pt 2): 133 Chan FKL, Wong VW, Suen BY, et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: a double blind, randomized trial [abstract no. A732]. Gastroenterology 2006; 130 (4 Pt 2): 133
36.
Zurück zum Zitat Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004; 20(3): 321–31PubMedCrossRef Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004; 20(3): 321–31PubMedCrossRef
37.
Zurück zum Zitat Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16(4): 779–86PubMedCrossRef Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16(4): 779–86PubMedCrossRef
38.
Zurück zum Zitat Goldstein JL, Huang B, Amer F, et al. Ulcer recurrence in highrisk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004; 26(10): 1637–43PubMedCrossRef Goldstein JL, Huang B, Amer F, et al. Ulcer recurrence in highrisk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004; 26(10): 1637–43PubMedCrossRef
39.
Zurück zum Zitat Rahme E, Bardou M, Dasgupta K, et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology 2007; 46(2): 265–72PubMedCrossRef Rahme E, Bardou M, Dasgupta K, et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology 2007; 46(2): 265–72PubMedCrossRef
40.
Zurück zum Zitat Goldstein JL, Aisenberg J, Berger M, et al. Effect of concomitant (81mg qd) on incidence of gastric and/or duodenal ulcers in healthy subjects taking celecoxib or naproxen: a randomized placebo-controlled trial [abstract no. A562]. Gastroenterology 2006; 130 (4 Pt 2): 81 Goldstein JL, Aisenberg J, Berger M, et al. Effect of concomitant (81mg qd) on incidence of gastric and/or duodenal ulcers in healthy subjects taking celecoxib or naproxen: a randomized placebo-controlled trial [abstract no. A562]. Gastroenterology 2006; 130 (4 Pt 2): 81
41.
Zurück zum Zitat Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364(9435): 665–74PubMedCrossRef Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364(9435): 665–74PubMedCrossRef
42.
Zurück zum Zitat Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002; 359: 14–22PubMedCrossRef Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002; 359: 14–22PubMedCrossRef
43.
Zurück zum Zitat Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12: 3789–92PubMed Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12: 3789–92PubMed
44.
Zurück zum Zitat Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal antiinflammatory drugs. Aliment Pharmacol Ther 2004; 20(10): 1091–7PubMedCrossRef Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal antiinflammatory drugs. Aliment Pharmacol Ther 2004; 20(10): 1091–7PubMedCrossRef
45.
Zurück zum Zitat Pilotto A, Franceschi M, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res 2003; 15(6): 494–9PubMed Pilotto A, Franceschi M, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res 2003; 15(6): 494–9PubMed
46.
Zurück zum Zitat Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115:787–96PubMed Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115:787–96PubMed
47.
Zurück zum Zitat Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25: 373–96PubMedCrossRef Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25: 373–96PubMedCrossRef
48.
Zurück zum Zitat Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 126: 1171–8CrossRef Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 126: 1171–8CrossRef
49.
Zurück zum Zitat Pietzsch M, Theuer S, Haase G, et al. Results of systematic screening for serious gastrointestinal bleeding associated with NSAIDs in Rostock hospitals. Int J Clin Pharmacol Ther 2002; 40: 111–5PubMed Pietzsch M, Theuer S, Haase G, et al. Results of systematic screening for serious gastrointestinal bleeding associated with NSAIDs in Rostock hospitals. Int J Clin Pharmacol Ther 2002; 40: 111–5PubMed
50.
Zurück zum Zitat van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002; 24(3): 100–3PubMedCrossRef van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002; 24(3): 100–3PubMedCrossRef
51.
Zurück zum Zitat Arboleya LR, de la Figuera E, Soledad Garcia M, et al. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of coxibs. Curr Med Res Opin 2003; 19(4): 278–87PubMedCrossRef Arboleya LR, de la Figuera E, Soledad Garcia M, et al. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of coxibs. Curr Med Res Opin 2003; 19(4): 278–87PubMedCrossRef
52.
Zurück zum Zitat Sturkenboom MCJM, Burke TA, Tangelder MJD, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18: 1137–47PubMedCrossRef Sturkenboom MCJM, Burke TA, Tangelder MJD, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18: 1137–47PubMedCrossRef
53.
Zurück zum Zitat Hartneil NR, Flanagan PS, MacKinnon NJ, et al. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2004; 2(3): 171–80CrossRef Hartneil NR, Flanagan PS, MacKinnon NJ, et al. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2004; 2(3): 171–80CrossRef
54.
Zurück zum Zitat Pilotto A, Franceschi M, Vitale DF, et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of nonselective NSAIDs or coxibs. Aliment Pharmacol Ther 2005; 22(2): 147–55PubMedCrossRef Pilotto A, Franceschi M, Vitale DF, et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of nonselective NSAIDs or coxibs. Aliment Pharmacol Ther 2005; 22(2): 147–55PubMedCrossRef
55.
Zurück zum Zitat Teeling M, Bennett K, Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?. Br J Clin Pharmacol 2004; 57(3): 337–43PubMedCrossRef Teeling M, Bennett K, Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?. Br J Clin Pharmacol 2004; 57(3): 337–43PubMedCrossRef
56.
Zurück zum Zitat Silvani MC, Motola M, Poluzzi E, et al. Gastrointestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy. Eur J Clin Pharmacol 2006; 62: 235–41PubMedCrossRef Silvani MC, Motola M, Poluzzi E, et al. Gastrointestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy. Eur J Clin Pharmacol 2006; 62: 235–41PubMedCrossRef
57.
Zurück zum Zitat Hur C, Chan AT, Tramontano AC, et al. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother 2006; 40(6): 1052–63PubMedCrossRef Hur C, Chan AT, Tramontano AC, et al. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother 2006; 40(6): 1052–63PubMedCrossRef
58.
Zurück zum Zitat Motola D, Vaccheri A, Silvani MC, et al. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004; 60(10): 731–8PubMedCrossRef Motola D, Vaccheri A, Silvani MC, et al. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004; 60(10): 731–8PubMedCrossRef
Metadaten
Titel
Inappropriate Prevention of NSAID-Induced Gastrointestinal Events Among Long-Term Users in the Elderly
verfasst von
Dr Angel Lanas
Angel Ferrandez
Publikationsdatum
01.02.2007
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 2/2007
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724020-00004

Weitere Artikel der Ausgabe 2/2007

Drugs & Aging 2/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.